2023 Satellite - Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Best Practices for Successful Outcomes - OnDemand-Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Best Practices for Successful Outcomes in Patients with Heart Failure

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Best Practices for Successful Outcomes in Patients with Heart Failure

Video Transcription

Video Summary

Summary 1:<br /><br />The first video transcript summarizes a discussion on Van Stuyren and amyloid cardiomyopathy, focusing on best practices for successful outcomes in heart failure patients. Dr. Ahmed Masri presents on raising awareness, screening, and diagnosing ATR-CM patients with clinical heart failure. He emphasizes the importance of early diagnosis, clinical evaluation, and the use of imaging tools. Dr. Masri also highlights the need for awareness and early detection in minority populations, particularly those of Western African ancestry and Afro-Caribbeans. He discusses best practices for managing ATR-CM patients, including anticoagulation, pacemakers, and the use of MRAs and SGLT2 inhibitors. The speaker also discusses emerging therapies, such as TTR stabilization with drugs like tafamadis and acromidus, as well as small interfering RNA therapy and CRISPR. Data from trials show significant reductions in mortality and hospitalizations with tafamadis, as well as improvements in walking distance and quality of life with other therapies. The speaker concludes by emphasizing early detection, ongoing research, and the potential benefits of emerging therapies.<br /><br />Summary 2:<br /><br />The second video transcript focuses on treatment options and case presentations related to cardiomyopathy due to amyloid and heart failure. The speaker discusses CRISPR as a treatment option, as well as anti-amyloid therapies using immunized monoclonal antibodies. Collaboration between base science colleagues and the pharmaceutical industry is emphasized for developing effective therapies. Three case presentations are discussed, including a 61-year-old man diagnosed with AL amyloidosis, a 93-year-old man with v122i and no cardiac symptoms, and a 60-year-old man with suspected amyloidosis and v122i. It is suggested that patients with v122i who are older and asymptomatic may not need further evaluation. The speaker concludes by highlighting the need for ongoing follow-up and individualized treatment plans for patients with amyloidosis.

Keywords

amyloid cardiomyopathy

heart failure patients

ATR-CM

clinical evaluation

imaging tools

minority populations

TTR stabilization

tafamadis

CRISPR

emerging therapies